CME/CE INFORMATION
Rural Health Clinical Congress Spring 2023
Saturday, May 20, 2023 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT
HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:
- Step 1: Log In
Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
If you do not know your password, follow the link to reset it. - Step 2: Complete Evaluation(s)
Click the Evaluations tab on the left. You will see a listing of each session. Click the blue Take Evaluation button and complete the evaluation form for each session you attended. - Step 3: View and Print Certificate(s)
After you’ve completed the evaluations, click the blue Print Certificate button to view and print your CME/CE certificates.
Navigating Moderate-to-Severe Asthma Management: Strategies for Reducing Disparities
and Optimizing Care in Rural and Underserved Communities
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Bristol Myers Squibb; Pfizer and Myovant Sciences, Inc.; Regeneron Pharmaceuticals, Inc. and Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
LEARNING OBJECTIVES
- Integrate the latest guidance into the care of patients with moderate-to-severe asthma
- Develop evidence-based treatment plans for patients with moderate-to-severe asthma that consider exacerbation risks, comorbidities, and quality of life
- Apply strategies including self-management education and asthma action plans to improve asthma care and management in rural and underserved settings
FACULTY
Wanda Phipatanakul, MD, MS
S. Jean Emans Professor of Pediatrics
Harvard Medical School
Attending Physician and Director, Clinical Research Center
Division of Immunology
Boston Children's Hospital
Boston, MA
Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Wanda Phipatanakul, MD, MS, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Genentech, Inc., GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., and Sanofi.
Barbara P. Yawn, MD, MSc, FAAFP, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceuticals, Pulmonx, and Teva Pharmaceuticals; contracted research for AstraZeneca Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, and Teva Pharmaceuticals.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.
Optimizing Outcomes for Patients With Uterine Fibroids:
Strategies for Overcoming Barriers to Equity in Rural and Underserved Communities
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Bristol Myers Squibb; Pfizer and Myovant Sciences, Inc.; Regeneron Pharmaceuticals, Inc. and Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
This session is supported by an independent medical education grant from Pfizer and Myovant Sciences, Inc.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
LEARNING OBJECTIVES
- Assess the symptom burden of uterine fibroids and its impact on quality of life
- Evaluate the latest clinical trial data on the efficacy and safety of novel hormonal therapies for uterine fibroids
- Apply the latest clinical evidence and guideline recommendations into the medical management of uterine fibroids
- Discuss strategies for overcoming barriers and improving uterine fibroids care in rural and underserved communities
FACULTY
Mindy S. Christianson, MD, MBA
Section Head, Reproductive Endocrinology and Infertility
Cleveland Clinic, Women’s Health Institute
Cleveland, OH
Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Mindy S. Christianson, MD, MBA, has no relevant financial relationships to disclose.
Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.
Improving Recognition and Management of Myelodysplastic Syndromes
in Rural and Underserved Communities: A Primary Care Approach
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Bristol Myers Squibb; Pfizer and Myovant Sciences, Inc.; Regeneron Pharmaceuticals, Inc. and Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
This session is supported by an independent medical education grant from Bristol Myers Squibb.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
LEARNING OBJECTIVES
- Identify signs and symptoms as well as strategies to improve the timely diagnosis and early referral of patients with suspected myelodysplastic syndromes (MDS)
- Evaluate the safety and efficacy of new and emerging therapies for lower-risk MDS
- Apply patient-centered strategies for improving the management and monitoring of patients with lower-risk MDS
- Integrate evidence-based strategies for improving access to care and collaborative management of patients with MDS who reside in rural and underserved communities
FACULTY
Gail J. Roboz, MD
William S. Paley Professor of Medicine
Weill Cornell Medicine
Director, Clinical and Translational Leukemia Program
NewYork-Presbyterian Hospital
New York, NY
Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Gail J. Roboz, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., Amgen, Inc., Argenx, AstraZeneca Pharmaceuticals, Bluebird Bio, Inc., Blueprint Medicines, Bristol Myers Squibb, Caribou Biosciences, Celgene Corporation, Daiichi Sankyo, Ellipses Pharma, GlaxoSmithKline, Janssen Pharmaceuticals, Jasper Therapeutics, Jazz Pharmaceuticals, Molecular Partners, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Roche, Syndax Pharmaceuticals, Inc., and Takeda Pharmaceuticals (Independent Review Committee Chair).
Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.
Managing Children and Adults With Moderate-to-Severe Atopic Dermatitis: Addressing Treatment
Challenges and Improving Access to Care in Rural and Underserved Communities
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Bristol Myers Squibb; Pfizer and Myovant Sciences, Inc.; Regeneron Pharmaceuticals, Inc. and Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
This session is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals, Inc.
TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
LEARNING OBJECTIVES
- Explain the pathophysiology and immunologic factors associated with atopic dermatitis
- Apply current evidence and recommendations into individualized treatment plans for adult and pediatric patients with atopic dermatitis
- Summarize the latest clinical trial data on the efficacy and safety of novel treatment options for atopic dermatitis
- Implement strategies to improve multidisciplinary care of atopic dermatitis in rural and underserved communities
FACULTY
Andrew F. Alexis, MD, MPH
Professor of Clinical Dermatology
Vice-Chair, Diversity and Inclusion for the Department of Dermatology
Weill Cornell Medical College
New York, NY
Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Andrew F. Alexis, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., Allergan, Almirall, Amgen, Arcutis Biotherapeutics, Bausch Health, Bristol Myers Squibb, Cara Therapeutics, Inc., Castle Biosciences, Cutera, Dermavant Sciences, Eli Lilly, EPI Health, Galderma, Incyte Corporation, Janssen Pharmaceuticals, LEO Pharma, Ortho Pharmaceuticals, Pfizer, Inc., Sanofi-Regeneron, Swiss American, UCB, and VYNE Therapeutics; speakers’ bureau for Bristol Myers Squibb, Pfizer, Inc., Regeneron Pharmaceuticals, and Sanofi Genzyme.
Barbara P. Yawn, MD, MSc, FAAFP, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceuticals, Pulmonx, and Teva Pharmaceuticals; contracted research for AstraZeneca Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, and Teva Pharmaceuticals.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.
Advancing Equity in Inflammatory Bowel Disease Care: Evidence-Based Strategies
for Improving Recognition and Management in Rural and Underserved Communities
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Bristol Myers Squibb; Pfizer and Myovant Sciences, Inc.; Regeneron Pharmaceuticals, Inc. and Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
This session is supported by independent medical education grants from AbbVie, Inc. and Takeda Pharmaceuticals U.S.A., Inc.
TARGET AUDIENCE
This
activity is designed specifically for primary care clinicians,
registered nurses, and advanced practice registered nurses who care for
patients from rural and underserved areas.
LEARNING OBJECTIVES
- Describe the initial diagnostic workup for patients with suspected inflammatory bowel disease (IBD)
- Summarize treatment options available to patients with IBD, including their potential side effects and follow-up care
- Apply evidence-based treatment strategies for patients with IBD that reflect the latest clinical evidence and guideline recommendations
- Identify strategies for improving access to care and management for rural and underserved populations with IBD
FACULTY
Adam S. Cheifetz, MD
Professor of Medicine
Harvard Medical School
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Boston, MA
Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing
Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative
adhere to the ACCME’s Standards for Integrity and Independence in
Accredited Continuing Education. Postgraduate Institute for Medicine
requires faculty, planners, and others in control of educational content
to disclose all their financial relationships with ineligible companies
(commercial interests). All identified conflicts of interest (COI) are
thoroughly vetted and mitigated according to Postgraduate Institute for
Medicine policy. Postgraduate Institute for Medicine is committed to
providing its learners with high quality accredited continuing education
activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of an
ineligible company.
Faculty
The
faculty reported the following relevant financial relationships with
ineligible entities related to the educational content of this CE
activity:
Adam S. Cheifetz, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from AbbVie, Inc. and Bristol Myers Squibb; consultant/advisory board member for AbbVie, Inc., Artizan, Artugen, Bristol Myers Squibb, Clario, Equillium, Fresenius Kabi, Fzata, Janssen Pharmaceuticals, Pfizer, Inc., ProciseDx, Prometheus Laboratories, Protagonist, Samsung Bioepis, Spherix Global Insights, and Takeda Pharmaceuticals.
Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications. The opinions expressed in the educational
activity are those of the faculty and do not necessarily represent the
views of the planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
DISCLAIMER
Participants
have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The
information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
and/or dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other authorities.
CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.
Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at inquiries@pimed.com.
Optimizing Short Bowel Syndrome Management in Rural and Underserved Settings:
Patient Insight and Collaborative Pathways for Delivering Evidence-Based Care
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie, Inc.; Bristol Myers Squibb; Pfizer and Myovant Sciences, Inc.; Regeneron Pharmaceuticals, Inc. and Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
This session is supported by an independent medical education grant from Takeda Pharmaceuticals U.S.A., Inc.
TARGET AUDIENCE
This
activity is designed specifically for primary care clinicians,
registered nurses, and advanced practice registered nurses who care for
patients from rural and underserved areas.
LEARNING OBJECTIVES
- Describe the pathophysiology and associated risk factors of short bowel syndrome
- Assess available pharmacologic options for patients with short bowel syndrome
- Apply individualized patient-centered strategies for the management of short bowel syndrome to reduce the need for parenteral support and improve clinical outcomes and quality of life
- Utilize evidence-based strategies to improve access to care and interdisciplinary management of patients with short bowel syndrome who reside in rural and underserved communities
FACULTY
John K. DiBaise, MD
Professor of Medicine
Mayo Clinic School of Medicine
Consultant, Division of Gastroenterology and Hepatology
Mayo Clinic
Phoenix, AZ
Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing
Education activity is 1.0 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative
adhere to the ACCME’s Standards for Integrity and Independence in
Accredited Continuing Education. Postgraduate Institute for Medicine
requires faculty, planners, and others in control of educational content
to disclose all their financial relationships with ineligible companies
(commercial interests). All identified conflicts of interest (COI) are
thoroughly vetted and mitigated according to Postgraduate Institute for
Medicine policy. Postgraduate Institute for Medicine is committed to
providing its learners with high quality accredited continuing education
activities and related materials that promote improvements or quality
in healthcare and not a specific proprietary business interest of an
ineligible company.
Faculty
The
faculty reported the following relevant financial relationships with
ineligible entities related to the educational content of this CE
activity:
John K. DiBaise, MD, has disclosed the following relevant financial relationships: grant/research support from Zealand Pharmaceuticals; consultant/advisory board member for Baxter Healthcare, Napo Pharmaceuticals, Inc., NorthSea Therapeutics, and Takeda Pharmaceuticals.
Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications. The opinions expressed in the educational
activity are those of the faculty and do not necessarily represent the
views of the planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
DISCLAIMER
Participants
have an implied responsibility to use the newly acquired information to
enhance patient outcomes and their own professional development. The
information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
and/or dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other authorities.
CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.
Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at inquiries@pimed.com.
OBTAINING CME/CE CREDIT
1. Register online.
2. Attend the live program in its entirety.
3. Complete an online program evaluation for each session you attend.
4. Download and/or print your certificate(s) of completion.
MEDIA
Internet activity
COMPUTER SYSTEM REQUIREMENTS
- System checker: Must meet all requirements of Digitell Live Events Platform
- Operating system: Windows or Macintosh
- Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
- Hardware: computer, smartphone, or tablet
- Broadband Internet connection: high-speed connection preferable
FEE INFORMATION
There is no fee for this educational activity.
COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.